Risk factors in patients with non-alcoholic fatty liver disease associated with arterial hypertension, overweight and obesity

Purpose of the study was to investigate the features of the occurrence of risk factors in patients with non-alcoholic fatty liver disease associated with arterial hypertension, overweight and obesity. Material and methods. The object of the study was the data of 14 393 case histories of patients with arterial hypertension (AH), non-alcoholic fatty liver disease (NFLD), overweight body (OB) and obesity, examined and treated at the clinic of the Federal Research Center for Fundamental and Translational Medicine (Novosibirsk). Results and discussion. Features of biochemical parameters in patients with NFLD with AH, OB and obesity were studied in comparison with patients with isolated diseases. It was shown that in patients, in case of the presence of this comorbidity, the value of transsystem polymorbidity is statistically significantly increased compared with groups of patients with isolated diseases. It was established that patients with concomitant diseases have higher, statistically significant values of systolic and diastolic blood pressure, body mass index. They have higher concentrations of total cholesterol, triglycerides, high density lipoprotein cholesterol, glucose, uric acid in the blood serum, higher atherogenic index. A study of the frequency of occurrence of risk factors in the groups showed the highest frequency values in patients with associated diseases: high blood pressure, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, hypoalphacholesterolemia, hyperlipidemia, increased atherogenic index, hyperglycemia, hyperuricemia, the higher levels of C-reactive protein, which indicates that with associated pathology, changes in carbohydrate, lipid and purine metabolism are more pronounced. These changes are factors that aggravate the course of the pathology and are risk factors for the development of diabetes mellitus, atherosclerosis and associated conditions, which requires a personalized approach to the treatment and prevention of this category of patients. The results of this study can form the basis for the development of new medical technology for assessing the severity of condition in patients with non-alcoholic fatty liver disease combined with arterial hypertension, overweight and obesity.

1. Belyalov F.I. Treatment of internal diseases in conditions of comorbidity. Irkutsk, 2014. 308 р. [In Russian].
2. Nikolaev Yu.A., Sevost'yanova E.V., Mitrofanov I.M., Polyakov V.Ya., Dolgova N.A. Features of polymorbidity in patients of the therapeutic clinic of cardiological and gastroenterological profiles. Terapevticheskiy arkhiv = Therapeutic archive. 2016; 1: 40-45. [In Russian].
3. Oganov R.G. Vascular сomorbidity: general approaches to prevention and treatment. Ratsional'naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2015; 11 (1): 4-7. [In Russian].
4. Boyd C.M., Reider L., Frey K.,  Scharfstein D., Leff B.,  Wolff J., Groves C., Karm L.,  Wegene S., Marsteller J., Boul C. The effects of guided care on the perceived quality of health care for multi-morbid older persons: 18-month outcomes from a cluster-randomized controlled trial. J. Gen. Intern. Med. 2010; 25: 235–242. doi: 10.1007/s11606-009-1192-5
5. Nikolaev Yu.A., Gevorgyan M.M., Kozaruk T.V., Kuznetsova A.P., Polyakov V.Ya. Features of clinical-biochemical and immunological indices in patients with hypertension, alien residents of the North, combined with diseases of the hepatobiliary system. Byulleten' Sibirskogo otdeleniya Rossiyskoy akademii meditsinskikh nauk = Bulletin of Siberian Branch of Russian Academy of Medical Sciences. 2012; 32 (4): 66-71. [ In Russian].
6. Sevost'yanova E.V., Nikolaev Yu.A., Mitrofanov I.M., Polyakov V.Ya. Features of polymorbidity in patients with arterial hypertension. Arterial'naya gipertenziya = Arterial Hypertension. 2019; 25 (2): 200-208. [In Russian].
7. Lazebnik L.B., Konev Yu.V., Efremov L.I. The main problem of geriatrics is the multiplicity of diseases in an elderly patient. Klinicheskaya gerontologiya = Clinical gerontology. 2019; 25 (1-2): 4–9. [In Russian].
8. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Global guidelines of the World gastroenterological organization. June 2012. Available at: https://www.worldgastroenterology.org/UserFiles/file/guidelines/nafld-nash-russian-2012.pdf [In Russian].
9. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. Chapman M.J., De Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R., Riccardi G., Richter D.J., Sabatine M.S., Taskinen M.R., Tokgozoglu L., Wiklund O.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020 J; 41 (1): 111-188. doi: 10.1093/eurheartj/ehz455
10.  Drapkina O.M., YAfarova A.A. Non-alcoholic fatty liver disease and cardiovascular risk: state of the problem. Racional'naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2017; 13 (5): 645-650. [In Russian].
11. Cherkashina E.A., Petrenko L.V., Evstigneeva A.YU. Non-alcoholic fatty liver disease: pathogenesis, diagnosis, treatment. Ul'yanovskiy mediko-biologicheskiy zhurnal = Ulyanovsk Medico-Biological Journal. 2014; (1): 35-46. [In Russian].
12. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008; 51 (11): 1947–1953. doi: 10.1007/s00125-008-1135-4
13. Ivashkin V.T., Drapkina O.M., Pavlov Ch.S., Bakulin I.G., Korneeva O.N. Non-alcoholic steatohepatitis in metabolic syndrome. Consilium medicum. 2007; (2): 18–21. [In Russian].
14. Asrih M., Jornayvaz F.R. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol. Cell. Endocrinol. 2015; 418: 55-65. doi: 10.1016/j.mce.2015.02.018
15. Kanwar P., Kowdley K.V. The metabolic syndrome and its influence on nonalcoholic steatohepatitis. Clin. Liver Dis. 2016; 20 (2): 225–243. doi: 10.1016/j.cld.2015.10.002 
16. Stacenko M.E., Turkina S.V., Kosivcova M.A., Tyshchenko I.A. Non-alcoholic fatty liver disease as a multisystem disease. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta = Journal of the Volgograd State Medical University. 2016; (2): 58-66. [In Russian].
17. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64 (1): 73–84. doi: 10.1002/hep.28431

Nikolaev Yu.A., e-mail: nicol@centercem.ru